Prevention of VZV reactivation using long-term low-dose valacyclovir after allogeneic hematopoietic stem cell transplantation.
Phase 2
- Conditions
- allogeneic hematopoietic stem cell transplantation recipients
- Registration Number
- JPRN-C000000348
- Lead Sponsor
- Japan Hematology & Oncology Clinical Study Group (J-HOCS)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with hematological malignancies not in remission. Severe organ dysfunction
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of VZV reactivation within 2 years after transplantation.
- Secondary Outcome Measures
Name Time Method